Kolexia
Gibot Sebastien Anesthesie-réanimation
Gibot Sebastien
Anesthesie-réanimation
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
157 Activités
17 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sepsie Choc septique Choc COVID-19 Inflammation Maladie grave Pneumopathie infectieuse Infarctus Syndrome de détresse respiratoire de l'adulte

Collaborateurs

Voir plus
Lemarie Jeremie
Lemarie Jeremie
Hôpital Hôtel-Dieu Nantes, Nantes, France
Bollaert Pierre
Bollaert Pierre
Hôpital Central, Nancy, France
Conrad Marie
Conrad Marie
Clinique Bellefontaine Clinea, Nancy, France
Francois Bruno
Francois Bruno
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
A+A
4 collaboration(s)
Dernière en 2021
Schlesinger Group France
2 collaboration(s)
Dernière en 2022
Pfizer
1 collaboration(s)
Dernière en 2022
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
RENAGRAF: Factors for Impairment of Renal Graft Function in Intensive Care
Essai Clinique (CHU Nancy)   06 février 2024
Santé. Le chaos du choc septique expliqué par le Pr Gibot
Républicain Lorrain   16 décembre 2023
Fluid balance control in critically ill patients: results from as-treated analyses of POINCARE-2 randomized trial.
Critical care (London, England)   06 novembre 2023
Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.
Frontiers in medicine   29 août 2023
Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.
Intensive care medicine experimental   14 août 2023
One-year prognosis of the elderly with at least one organ failure treated in the ICU
Proceedings of Reanimation 2023, the French Intensive Care Society International Congress   14 juin 2023
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
The Lancet. Respiratory medicine   31 mai 2023
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
EClinicalMedicine   31 mai 2023
ESSENTIAL: Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features
Essai Clinique (Inotrem)   02 mai 2023
ASTONISH: Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
Essai Clinique (Inotrem)   07 avril 2023